| Request a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Commercial Opportunities from an Aging Population: Epidemiology market andpipeline analysis across seven major indications, evaluates the benefits ofmarketing to seniors for the pharmaceutical industry. Globally, the number ofolder people will increase from 606m in 2000 to 1.9bn in 2050 and as a resulthealthcare needs will increase and drugs will be used for longer. This report analyzes commercial opportunities within the 'gray market' and shows how companies can meet these needs and keep company profits high.Current and future growth prospects are examined for pharmaceutical companies to2008 in seven major indications particularly associated with seniors. These areacute ischemic stroke, Alzheimer' s disease, arthritis, diabetes, male sexualdysfunction, osteoporosis and prostate cancer. Cumulatively, the total value ofthese markets was approximately $42bn in 2002 and this figure is set to risedramatically. TABLE OF CONTENTS
Executive Summary- Quantifying the 'gray market' opportunity
- Acute ischemic stroke
- Alzheimer' s disease
- Arthritis
- Diabetes
- Male sexual dysfunction
- Osteoporosis
- Prostate cancer
Chapter 1 Quantifying the 'gray market' - opportunity
- Summary
- Introduction
- Drivers of gray market growth
- Demographic trends: an aging population
- Healthcare needs increase with age
- The prevalence of chronic diseases is significantly higher among seniors
- Drugs will be used for longer as life expectancy increases
- Seniors' influence on the prescribing process
- Exploiting increased contact between seniors and physicians
- Harnessing the power of the web to communicate with seniors
- Internet use is already promoting patient-physician interaction
- Meeting seniors. health information needs
- Pharmaceutical industry online initiatives targeting seniors . Novartis.healthandage.com
Chapter 2 Acute ischemic stroke- Summary
- Disease overview
- Epidemiology
- Market analysis: focus on antithrombotics
- Activase (alteplase)
- Pipeline analysis
- Unmet needs in acute therapy
- Failure of neuroprotective agents
- Are antithrombotics the answer?
- Antithrombotics in development for acute ischemic stroke
- ReoPro (abciximab)
- Retavase (reteplase)
Chapter 3 Alzheimer' s disease- Summary
- Disease overview
- Epidemiology
- Market analysis
- Aricept (donepezil)
- Exelon (rivastigmine)
- Reminyl (galantamine)
- Ebixa (memantine)
- Late-stage pipeline analysis
- Cere (cerebrolysin)
- COGNIShunt
- NS-2330
Chapter 4 Arthritis- Summary
- Disease overview
- Epidemiology
- Market analysis
- Celebrex (celecoxib)
- Vioxx (rofecoxib)
- Bextra (valdecoxib)
- Remicade (infliximab)
- Pipeline analysis
- Prexige (lumiracoxib)
- CDP-870
Chapter 5 Diabetes- Summary
- Disease overview
- Epidemiology
- Market analysis
- Class dynamics
- Sulfonylureas
- Biguanides
- Thiazolidinediones
- Prandial glucose regulators
- Alfa glucosidase inhibitors
- Insulins
- Monotherapy versus combination therapy
- Leading and new products
- Avandia (rosiglitazone)
- Novolin (insulin)
- Humalog (insulin lispro)
- Lantus (insulin glargine)
- Pipeline analysis
- Exubera (inhaled insulin)
- AERx insulin Diabetes Management System (inhaled insulin)
- Oralin (transoral insulin)
- HIM2 (oral insulin)
Chapter 6 Male sexual dysfunction- Summary
- Disease overview
- Loss of libido
- Erectile dysfunction
- Priapism
- Peyronie.s disease
- Premature and delayed ejaculation
- Epidemiology
- Market analysis
- Viagra (sildenafil)
- Cialis (tadalafil)
- Levitra/Nuviva (vardenafil)
- Pipeline analysis
- Alibra (alprostadil + prazosin)
- Alprox-TD (alprostadil)
- Dapoxetine
- PNU-83757
Chapter 7 Osteoporosis- Summary
- Disease overview
- Pathophysiology and etiology
- Epidemiology
- Methodological difficulties in assessing prevalence
- Prevalence of osteoporosis and osteopenia in post-menopausal women
- Prevalence of osteoporosis and osteopenia in men
- Market analysis
- Impact of the Women.s Health Initiative on osteoporosis therapy
- Leading and new product sales to 2008
- Premarin family (conjugated estrogens)
- Fosamax (alendronate)
- Actonel (risedronate)
- Evista (raloxifene)
- Forteo (teriparatide)
- Pipeline analysis
- Boniva/Bondronat (ibandronate)
- Zometa (zoledronate)
- Lasofoxifene
- Premarin (conjugated estrogens) + bazedoxifene
Chapter 8 Prostate cancer- Summary
- Disease overview
- Epidemiology
- Market analysis
- Zoladex (goserelin)
- Casodex (bicalutamide)
- Lupron (leuprolide)
- Pipeline analysis
- Plenaxis (abarelix depot)
- Atrasentan
- Provenge (aberalix depot)
Chapter 9 Appendix- References
- Alzheimer.s disease
- Male sexual dysfunction
- Osteoporosis
- Prostate cancer
- Index
List of Figures- Figure 1.1: Average annual growth rates of the total population and thepopulation in broad ag groups, by major area, 2000-50 (median variant)
- Figure 1.2: The aging female population provides expanding opportunitiesin women.s health
- Figure 1.3: Healthcare spend increases with age
- Figure 1.4: Life expectancy at birth is rising
- Figure 1.5: Seniors visit physicians more frequently than their youngercounterparts
- Figure 1.6: The rate of Internet uptake is greatest among seniors
- Figure 1.7: Online seniors are approaching physicians with informationfrom the Internet
- Figure 1.8: Online seniors are searching for information on age-relateddiseases
- Figure 1.9: Novartis. www.healthandage.com
- Figure 2.10: Incidence of ischemic stroke in the seven major markets, 2002
- Figure 3.11: Prevalence of Alzheimer.s disease across the seven majormarkets, 2002
- Figure 6.12: Prevalence of male sexual dysfunction, 2002 1
- Figure 7.13: Prevalence of osteopenia and osteoporosis in thepost-menopausal population across the seven major markets, 2002 1
- Figure 7.14: Prevalence of osteopenia and osteoporosis in men aged 50+,2002 1
- Figure 8.15: Segmentation of prostate cancer patients among the sevenmajor markets, 2003 1
List of Tables- Table 2.1: Incidence of ischemic stroke in the seven major markets, 2002
- Table 2.2: Antithrombotics in development for acute ischemic stroke, 2003
- Table 3.3: Prevalence of Alzheimer.s disease across the seven majormarkets, 2002
- Table 3.4: Leading and new Alzheimer.s disease product sales, 2001-08
- Table 3.5: Late stage Alzheimer.s disease pipeline, 2003
- Table 4.6: Leading and new arthritis product sales, 2001-08
- Table 4.7: Late-stage arthritis pipeline, 2003
- Table 5.8: Prevalence of diabetes in the seven major markets, 2002 1
- Table 5.9: Leading and new diabetes product sales, 2001-08 1
- Table 5.10: Non-invasive insulin pipeline, 2003 1
- Table 6.11: Prevalence of male sexual dysfunction, 2002 (000s) 1
- Table 6.12: Prevalence of complete and severe erectile dysfunction in theover 40s, 2002 (000s)
- Table 6.13: Global forecasts of leading and innovative erectiledysfunction drugs to 2008
- Table 6.14: Male sexual dysfunction pipeline, phase II and above, 2003
- Table 7.15: Prevalence of osteopenia and osteoporosis in thepost-menopausal population across the seven major markets, 2002
- Table 7.16: Prevalence of osteopenia and osteoporosis in men aged 50+,2002
- Table 7.17: Leading and new product sales in the osteoporosis market,2002-08
- Table 7.18: Osteoporosis pipeline, phase II and above, 2003
- Table 8.19: Prevalence of prostate cancer in the seven major markets, 2003
- Table 8.20: Leading prostate cancer product sales, 2001-08
- Table 8.21: Late-stage prostate cancer pipeline, 2003
|
